QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
NASDAQ:VCNX

Vaccinex - VCNX Stock Forecast, Price & News

$0.75
+0.01 (+1.01%)
(As of 12/6/2022 11:46 AM ET)
Add
Compare
Today's Range
$0.71
▼
$0.75
50-Day Range
$0.44
▼
$0.74
52-Week Range
$0.41
▼
$2.28
Volume
928 shs
Average Volume
56,848 shs
Market Capitalization
$31.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VCNX stock logo

About Vaccinex (NASDAQ:VCNX) Stock

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Stock News Headlines

November 29, 2022 | americanbankingnews.com
Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update
November 28, 2022 | finance.yahoo.com
Vaccinex Announces $3.8 Million Private Placement
November 16, 2022 | finance.yahoo.com
Vaccinex Third Quarter 2022 Earnings: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021)
November 10, 2022 | finance.yahoo.com
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer
November 3, 2022 | finance.yahoo.com
Companies Like Vaccinex (NASDAQ:VCNX) Could Be Quite Risky
September 26, 2022 | uk.investing.com
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday By Benzinga - Investing.com UK
September 19, 2022 | reuters.com
VCNX.O - Vaccinex Inc | Stock Price & Latest News | Reuters
September 10, 2022 | reuters.com
VCNX.OQ - Vaccinex Inc | Stock Price & Latest News | Reuters
August 16, 2022 | seekingalpha.com
Vaccinex GAAP EPS of -$0.13 (NASDAQ:VCNX) - Seeking Alpha
August 15, 2022 | finance.yahoo.com
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs - Yahoo Finance
August 15, 2022 | finance.yahoo.com
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
August 10, 2022 | finance.yahoo.com
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation - Yahoo Finance
August 8, 2022 | streetinsider.com
Form 8-K VACCINEX, INC. For: Aug 06 - StreetInsider.com
August 8, 2022 | globenewswire.com
Vaccinex, Inc.'s Phase 2 “SIGNAL” Study to Evaluate - GlobeNewswire
August 8, 2022 | finance.yahoo.com
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation
July 30, 2022 | seekingalpha.com
Stocks To Watch: Eyes On Starbucks, Caterpillar, And Amgen - Seeking Alpha
July 29, 2022 | globenewswire.com
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease - GlobeNewswire
July 29, 2022 | finance.yahoo.com
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
July 29, 2022 | benzinga.com
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer's Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer's Disease
July 21, 2022 | finance.yahoo.com
Multiple insiders bought Vaccinex, Inc. (NASDAQ:VCNX) stock earlier this year, a positive sign for shareholders
May 31, 2022 | benzinga.com
Vaccinex Shares Spike Higher; Co. Tweeted 'Vaccinex is currently conducting 2 ongoing clinical trials: ou - Benzinga
May 25, 2022 | finance.yahoo.com
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET - Yahoo Finance
May 25, 2022 | finance.yahoo.com
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
May 18, 2022 | globenewswire.com
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update - GlobeNewswire
May 17, 2022 | finance.yahoo.com
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update - Yahoo Finance
See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Company Calendar

Last Earnings
11/08/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
CUSIP
N/A
CIK
1205922
Web
www.vaccinex.com
Phone
(585) 271-2700
Fax
585-271-2765
Employees
39
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,380,000.00
Net Margins
N/A
Pretax Margin
-38,736.00%
Return on Equity
-189.60%
Return on Assets
-157.63%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
4.04
Quick Ratio
4.04

Sales & Book Value

Annual Sales
$900,000.00
Price / Sales
35.41
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.24 per share
Price / Book
3.11

Miscellaneous

Outstanding Shares
42,660,000
Free Float
22,356,000
Market Cap
$31.87 million
Optionable
Not Optionable
Beta
1.23

Key Executives

  • Dr. Maurice Zauderer Ph.D.Dr. Maurice Zauderer Ph.D. (Age 76)
    Co-Founder, CEO, Pres & Director
    Comp: $374.9k
  • Mr. Scott E. Royer C.F.A. (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $242.15k
  • Dr. Ernest S. Smith Ph.D. (Age 50)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $264.74k
  • Dr. Elizabeth E. Evans Ph.D. (Age 49)
    COO and Sr. VP of Discovery & Translational Medicine
  • Dr. John E. Leonard Ph.D. (Age 75)
    Sr. VP of Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VCNX Stock - Frequently Asked Questions

How have VCNX shares performed in 2022?

Vaccinex's stock was trading at $1.04 at the start of the year. Since then, VCNX stock has decreased by 28.9% and is now trading at $0.7395.
View the best growth stocks for 2022 here.

Are investors shorting Vaccinex?

Vaccinex saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 129,900 shares, a drop of 50.9% from the October 31st total of 264,300 shares. Based on an average daily trading volume, of 71,900 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.6% of the company's shares are short sold.
View Vaccinex's Short Interest.

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our VCNX earnings forecast.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.12. The firm earned $0.05 million during the quarter.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.24%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $0.74.

How much money does Vaccinex make?

Vaccinex (NASDAQ:VCNX) has a market capitalization of $31.55 million and generates $900,000.00 in revenue each year. The company earns $-22,380,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The official website for the company is www.vaccinex.com. The company can be reached via phone at (585) 271-2700, via email at mrice@lifesciadvisors.com, or via fax at 585-271-2765.

This page (NASDAQ:VCNX) was last updated on 12/6/2022 by MarketBeat.com Staff